Cargando…

Efficacy and safety of rosuvastatin in the management of dyslipidemia

Rosuvastatin is a synthetic statin that represents an advance in the pharmacologic and clinical properties of statins. Relative to other statins, rosuvastatin possesses a greater number of binding interactions with HMG-CoA reductase and has a high affinity for the active site of the enzyme. As with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rubba, Paolo, Marotta, Gennaro, Gentile, Marco
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672446/ https://www.ncbi.nlm.nih.gov/pubmed/19436657

Ejemplares similares

Meta-analysis of the Efficacy and Safety of Adjunctive Rosuvastatin for Dyslipidemia in Patients with Schizophrenia
por: UNGVARI, Gabor S., et al.
Publicado: (2018)

The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia
por: Rhee, Moo-Yong, et al.
Publicado: (2017)

Efficacy and safety of co‐administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia
por: Jin, Xuan, et al.
Publicado: (2020)

Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights
por: Chilbert, Maya R, et al.
Publicado: (2022)

A comparative evaluation of safety and efficacy of rosuvastatin, simvastatin, and atorvastatin in patients of type 2 diabetes mellitus with dyslipidemia
por: Adsule, Samir Maruti, et al.
Publicado: (2009)

Effects of rosuvastatin combined with fasudil therapy on rabbits with dyslipidemia
por: Li, Zhiming, et al.
Publicado: (2015)

Comparison of the Efficacy of Rosuvastatin 5 mg and 10 mg in Patients of Type 2 Diabetes Mellitus With Dyslipidemia
por: Aleem, Mudassar, et al.
Publicado: (2022)

Comparison of Efficacy and Safety of Fixed Dose Combination of Rosuvastatin and Choline Fenofibrate to Fixed Dose Combination of Rosuvastatin and Fenofibrate in Patients of Mixed Dyslipidemia: A Randomized, Open-label, Multicentre Clinical Trial in Indian Population
por: Barkate, Hanmant, et al.
Publicado: (2018)

Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients
por: Saeedi, Ramesh, et al.
Publicado: (2015)

Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy
por: Tarantino, Nicola, et al.
Publicado: (2017)

Association between body shape index and small dense LDL particles in a cohort of mediterranean women: findings from Progetto ATENA
por: Gentile, Marco, et al.
Publicado: (2017)

Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia
por: Jung, Hae Won, et al.
Publicado: (2023)

Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Viljoen, Adie, et al.
Publicado: (2010)

Omega-3 fatty acids plus rosuvastatin improves endothelial function in South Asians with dyslipidemia
por: Mindrescu, Catalin, et al.
Publicado: (2008)

Cardiometabolic Risk Factors in Rosuvastatin-Treated Men with Mixed Dyslipidemia and Early-Onset Androgenic Alopecia
por: Krysiak, Robert, et al.
Publicado: (2021)

Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients
por: Rodríguez-Saldaña, Joel, et al.
Publicado: (2022)

Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin
por: Kim, Hyoeun, et al.
Publicado: (2020)

Efficacy and Safety of Coadministered Ezetimibe–Rosuvastatin plus Telmisartan in South Korean Patients with Dyslipidemia and Hypertension: A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase III Trial
por: Song, Zhao-Yan, et al.
Publicado: (2023)

Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong)
por: Park, Jin-Sun, et al.
Publicado: (2016)

Current Perspectives on rosuvastatin
por: Hu, Miao, et al.
Publicado: (2013)

Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients
por: Barakat, Lolwa, et al.
Publicado: (2013)

Efficacy and Safety of Nebivolol and Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Hyperlipidemia
por: Rhee, Moo-Yong, et al.
Publicado: (2020)

Antihypertensive effects of rosuvastatin in patients with hypertension and dyslipidemia: A systemic review and meta-analysis of randomized studies
por: Lee, Sungjae, et al.
Publicado: (2021)

The influence of the intestinal microflora to the efficacy of Rosuvastatin
por: Wang, Lijun, et al.
Publicado: (2018)

Comparison of the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy and Rosuvastatin Monotherapy on Lipoprotein in Patients With Type 2 Diabetes: Multicenter Randomized Controlled Study
por: Lee, Jiwoo, et al.
Publicado: (2020)

A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia
por: Kim, Min Chul, et al.
Publicado: (2023)

Efficacy of Polyphenols in the Management of Dyslipidemia: A Focus on Clinical Studies
por: Feldman, Francis, et al.
Publicado: (2021)

Effect and Safety of Rosuvastatin in Acute Ischemic Stroke
por: Heo, Ji Hoe, et al.
Publicado: (2016)

Management of dyslipidemia in children
por: Kalra, Sanjay, et al.
Publicado: (2009)

Real-World Effectiveness of Therapy With Rosuvastatin Combined With Fenofibric Acid in a Sample of Colombian Patients With Mixed Dyslipidemia
por: Machado-Duque, Manuel E., et al.
Publicado: (2020)

Contemporary Management of Dyslipidemia
por: Ferraro, Richard A., et al.
Publicado: (2022)

Dyslipidemia in women: etiology and management
por: Phan, Binh An P, et al.
Publicado: (2014)

Liquid Crystalline Nanoparticles for Nasal Delivery of Rosuvastatin: Implications on Therapeutic Efficacy in Management of Epilepsy
por: Ahmed, Mohammad Zubair, et al.
Publicado: (2020)

Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies
por: Chhabra, Manik, et al.
Publicado: (2022)

Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence
por: Perez-Calahorra, Sofía, et al.
Publicado: (2019)

Safety and efficacy of short-term dual antiplatelet therapy combined with intensive rosuvastatin in acute ischemic stroke
por: Deng, Ting, et al.
Publicado: (2023)

A Prospective Randomized, Double-Blind, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of Olmesartan/Amlodipine plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia: A LEISURE Study
por: Jo, Sang-Ho, et al.
Publicado: (2022)

A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy
por: Jeon, Eun-Seok, et al.
Publicado: (2022)

Global Trends in the Epidemiology and Management of Dyslipidemia
por: Liu, Tianxiao, et al.
Publicado: (2022)

Screening and Management of Dyslipidemia in Children and Adolescents
por: Schefelker, Juliette M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t1qvu6k1n3cqcbqs0t4nonv47b